Palonosetron plus dexamethasone in highly emetogenic chemotherapy: Pooled data from two Phase III trials

Future Oncology

Volumn 9, Issue 10, 2013, Pages 1451-1458

  Celio, Luigi ^a   Agustoni, Francesco ^a   Ricchini, Francesca ^a   Dotti, Katia ^a   Niger, Monica ^a   Braud, Filippo De ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

chemotherapy induced nausea and vomiting; dexamethasone; highly emetogenic chemotherapy; nausea; palonosetron; vomiting

Indexed keywords

ANTHRACYCLINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANISETRON; ONDANSETRON; PALONOSETRON;

ADULT; ARTICLE; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MANTEL HAENSZEL TEST; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; ONCOLOGY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RESEARCH; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; FEMALE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; QUINUCLIDINES; TREATMENT OUTCOME; VOMITING;

EID: 84885676946     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.153     Document Type: Article

References (35)

1. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N. Engl. J. Med. 358, 2482-2494 (2008). Concerns both preclinical and clinical aspects of chemotherapy-induced nausea and vomiting (CINV)
2. Roila F, Herrstedt J, Aapro M et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann. Oncol. 21(Suppl. 5), v232-v243 (2010)
3. Basch E, Prestrud AA, Hesketh PJ et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 29(31), 4189-4198 (2011)
4. Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agents. J. Natl. Cancer Inst. 83(9), 613-620 (1991)
5. Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann. Oncol. 18(2), 233-240 (2007) (Pubitemid 46323087)
6. Jordan K, Hinke A, Grothey A et al. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support. Care Cancer 15(9), 1023-1033 (2007) (Pubitemid 47340963)
7. Goedhals L, Heron HF, Kleisbauer JP, Pagani O, Sessa C. Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind placebo-controlled, comparative study. Ann. Oncol. 9(6), 661-666 (1998) (Pubitemid 28318201)
8. Latreille J, Pater J, Johnston D et al. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J. Clin. Oncol. 16(3), 1174-1178 (1998) (Pubitemid 28108755)
9. Tsukada H, Hirose T, Yokoyama A, Kurita Y. Randomized comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis. Eur. J. Cancer 37(18), 2398-2404 (2001) (Pubitemid 33097477)
10. Aapro M. 5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment. Oncology 69(2), 97-109 (2005) (Pubitemid 41376907)
11. Rojas C, Stathis M, Thomas AG et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth. Analg. 107(2), 469-478 (2008)
12. Aapro M, Grunberg SM, Manikhas GM et al. A Phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann. Oncol. 17(9), 1441-1449 (2006) (Pubitemid 44400384)
13. Saito M, Aogi K, Sekine I et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomized, comparative Phase III trial. Lancet Oncol. 10(2), 115-124 (2009). Phase III trial demonstrating the superiority of palonosetron in preventing delayed CINV caused by highly emetogenic chemotherapy
14. Eisenberg P, Figueroa-Vadillo J, Zamora R et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a Phase III, single-dose trial versus dolasetron. Cancer 98(11), 2473-2482 (2003) (Pubitemid 37466663)
15. Gralla R, Lichinitser M, Van Der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized Phase III trial comparing single doses of palonosetron with ondansetron. Ann. Oncol. 14(10), 1570-1577 (2003) (Pubitemid 37304615)
16. Likun Z, Xiang J, Yi B, Xin D, Tao ZL. A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults. Oncologist 16(2), 207-216 (2011)
17. Meta-analysis demonstrating that the use of palonosetron at the dose of 0.75 mg does not affect antiemetic outcome
18. Natale J, Cartmell A. Improved efficacy of a single-day regimen of palonosetron plus dexamethasone versus ondansetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting. Presented at: 40th American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition. Las Vegas, NV, USA, 4-8 December 2005 (Abstract 40)
19. Kubota K, Saito M, Aogi K et al. Control nausea with palonosetron versus granisetron both combined with dexamethasone in patients undergoing cisplatin (CDDP)- or anthracycline plus cyclophosphamide (AC/EC)-based regimens. Presented at: 35th ESMO Congress. Milan, Italy, 8-12 October 2010
20. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl Cancer Inst. 22(4), 719-748 (1959)
21. Navari RM. Management of chemotherapy-induced nausea and vomiting. Drugs 73(3), 249-262 (2013)
22. Shows the state-of-art knowledge about CINV
23. Kris MG, Tonato M, Bria E et al. Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy. Support. Care Cancer 19(Suppl. 1), S25-S32 (2011)
24. Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J. Clin. Oncol. 18(19), 3409-3422 (2000)
25. Hothersall JD, Moffat C, Connolly CN. Prolonged inhibition of 5-HT3 receptors by palonosetron results from surface receptor inhibition rather than inducing receptor internalization. Br. J. Pharmacol. 169(6), 1252-1262 (2013)
26. New evidence supporting a unique mechanism of action for palonosetron
27. Aapro M, Fabi A, Nolè F et al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann. Oncol. 21(5), 1083-1088 (2010)
28. Phase III trial evaluating a dexamethasone-sparing strategy in women receiving the anthracycline and cyclophosphamide combination
29. Celio L, Bonizzoni E, Bajetta E, Sebastiani S, Perrone T, Aapro MS. Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two Phase III trials. Support. Care Cancer 21(2), 565-573 (2013)
30. Meta-analysis demonstrating that a younger age does not affect the efficacy of a dexamethasone-sparing strategy in women undergoing anthracycline and cyclophosphamide treatment
31. Navari RM. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting: two new agents. J. Support. Oncol. 1(2), 89-103 (2003)
32. Celio L, Aapro M. Research on chemotherapy-induced nausea: back to the past for an unmet need? J. Clin. Oncol. 31(10), 1376-1377 (2013)
33. Nevidjon B, Chaudhary R. Controlling emesis: evolving challenges, novel strategies. J. Support. Oncol. 8(Suppl. 2), 1-10 (2010)
34. Longo F, Mansueto G, Lapadula V et al. Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy. Int. J. Clin. Pract. 66(8), 753-757 (2012)
35. The largest Phase II trial of palonosetron in combination with aprepitant in lung cancer patients treated with cisplatin over multiple cycles.